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SHORT COMMUNICATION
Todinated hydroxyphenyl and hydroxynaphthyl porphyrins as tumour
localisers
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The tumour localising and photosensitising properties of
various natural and synthetic porphyrins have led to the
quest for increasingly efficient agents for the phototherapy of
cancer (Chan et al., 1988; Bown et al., 1986). An ideal agent
for phototherapy should have good selectivity for neoplastic
tissues, a high yield of reactive species such as singlet oxygen
(Bown et al., 1986) and long wavelength stimulation for
deeper tissue penetration. Berenbaum et al. (1986) showed
that the synthetic meso-tetra (hydroxyphenyl) porphyrins
appeared to satisfy most of these requirements. These
authors, however, quantitated the effectiveness of their com-
pounds by their relative ability to induce necrosis in trans-
planted animal tumours after irradiation with light of the
appropriate wavelength.
Tissue distributions of injected porphyrins are usually car-
ried out by chemical recovery from the tissues followed by
HPLC or spectrophotometric analysis. These methods are
notoriously unreliable due to poor recovery and interference
from endogenous porphyrins.
Molecules with activated phenyl groups can be readily
halogenated. It should therefore be possible to iodinate hyd-
roxyphenyl porphyrins with radioactive iodine ('25I or 1231).
This would enable their distribution in tumour-bearing
animals to be determined. Furthermore, if a porphyrin was
found which showed high ratios of tumour/normal tissue
uptake, modern technoloy would allow kits to be prepared
for labelling with 1231 for gamma-camera diagnostic imaging.
The advantages of this would be: (a) that it would provide a
much needed simple diagnostic tool for cancer detection; and
(b) that it would enable a more rational calculation of the
optimum amounts of porphyrin required for the
phototherapy of various types of cancer and avoid photosen-
sitive reactions in normal tissues.
With the above in mind various hydroxyphenyl porphyrins
have been synthesised, labelled with 1251I and their distribution
in tumour-bearing mice determined. Furthermore, since it has
been previously shown that tetranaphthyl porphyrins were
better tumour localisers than the tetraphenyl derivatives
(Zanelli & Kaelin, 1981), a tetra-hydroxynaphthyl porphyrin
was also synthesised, iodinated and its distribution in the
same mouse-tumour model determined.
The 4-hydroxyphenyl and hydroxynaphthyl porphyrins
were prepared either by demethylation of the corresponding
4-methoxy compounds or hydrolysis of the 4-acetoxy
derivatives. The 4-hydroxy-1-naphthyl porphyrin is a new
compound and was prepared by demethylation of the 4-
methoxy precursor. All the methoxy- and acetoxy-precursors
were synthesised by the general method outlined by Alder et
al. (1967) and modified by Zanelli and Kaelin (1981).
lodination was carried out by the chloramine-T method
described by Bolton (1977). However, since these porphyrins
are not water soluble, they were dissolved in DMSO, and the
labelled compounds recovered using Sep-Pak cartriges (Mil-
lipore (UK) Ltd) eluted with methanol. lodination yields and
specific activities ranged from 57 to 75% and 5.6 to
10.7 MBq mmol ' respectively.
The iodinated porphyrins were injected i.v. in CBA male
mice bearing the carcinoma NT tumour subcutaneously
(Hewitt et al., 1976). The vehicle used to dissolve the por-
phyrins for injection consisted of DMSO (9%), ethanol
(19%) and water for injection (72%). This formulation was
chosen because it mimics closely the vehicle used for i.v.
infusion of some water-insoluble chemotherapeutic agents in
patients (e.g. Peptichemio, ISM Belfanti, Italy) and is well
tolerated by mice. All compounds were injected in volumes
of 0.1 ml and contained 7- 15 jig of porphyrin (- 130 kBq).
The animals were killed at various times after injection and
the blood, tumour and various normal organs collected,
weighed and counted for 1251 content together with the
appropriate standards.
The results are shown in Table I. The two hydroxyphenyl
porphyrins have very similar distributions. The liver and
spleen take up a high proportion of the injected activity
followed, in order of uptake, by the lungs and kidneys.
The tumours take up very little of either porphyrin. The
3-hydroxyphenyl porphyrin appears to be better than the
4-derivative in that at 30-48 h after injection the amount of
porphyrin per gram of tumour is slightly (but not signifi-
cantly) above blood levels.
The 4-hydroxynaphthyl porphyrin behaves rather
differently. Although here too there is very low uptake in the
tumour, this porphyrin is taken up in considerable quantities
by the spleen. It should be noted that following the trans-
plantation of the tumours, the mice's spleens became enlarg-
ed reaching about 3.5 times normal size by day 8 after
tumour transplantation. However, there was no correlation
either between spleen weight and tumour size, or spleen
weight and uptake of porphyrin. Table I shows the uptake of
the hydroxynaphthyl porphyrin in normal, non-tumour bear-
ing mice. The spleen uptake, although high is much lower
than that in tumour bearing mice.
In view of the high efficiency in inducing tumour necrosis
during phototherapy, as reported by Berenbaum et al. (1986),
it was surprising to find that so little of the compounds were
actually taken up by the tumours. The fact that the blood
activity was in general equal to or higher than the tumour
activity tends to suggest that the phototherapeutic effects of
these compounds may be due to their intrinsically high quan-
tum yield and mediated via the destruction of the blood
supply to the tumours. It should be borne in mind that the
present porphyrins, being iodinated, may have different dis-
tributions from the non-iodinated compounds used by Beren-
baum et al. (1986). However, iodination did not appear to
significantly alter their solubility, lipophilicity and spectral
characteristics. Moreover a simple calculation shows that, at
the specific activities achieved there was approximately one
atom of 1251 in 107 molecules of porphyrin and mass spectro-
scopy of cold-iodinated porphyrins showed a preponderance
of mono-iodinated molecules and a small proportion of di-
iodinated molecules.
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Table I
% injected doseg-' at time after injection (h)
Tissue 1 8 24 30 48
TPP-4(OH)
Blood 11.2±1.3 7.6±0.6 3.1±0.4 3.5±0.7 2.0±0.2
Liver 10.7±0.9 7.8±1.1 3.7±1.0 2.9±0.3 2.7±0.2
Spleen 7.8± 1.1 6.2± 1.2 2.2±0.1 2.2±0.5 1.3±0.4
Kidneys 3.9±0.3 3.3±0.3 2.8±0.3 2.5±0.4 1.8±0.3
Lungs 15.5±3.1 16.4±2.4 2.9±0.3 2.9±0.4 1.7±0.5
Tumour 2.6±0.7 2.0±0.2 2.6±0.5 1.7±0.5 1.9±0.3
Brain 0.165±0.062 0.20±0.071 0.14±0.033 0.125±0.041 0.0115±0.037
Skin 1.62±0.37 1.22±0.51 1.07±0.38 1.09±0.43 0.04±0.28
TPP-3(OH)
Blood 18.3±3.1 8.3±0.7 3.8±0.7 3.2±0.2 2.0±0.5
Liver 16.1±4.2 12.5± 1.1 8.9±1.2 12.1±0.9 7.5± 1.6
Spleen 8.4± 1.1 7.5±0.5 4.5±0.3 5.0±0.6 4.1± 1.0
Kidneys 4.7± 1.0 3.3±0.3 2.5±0.3 2.7±0.6 2.3±0.3
Lungs 11.7±0.9 6.1±0.8 3.3±0.3 4.0±0.5 2.6±0.1
Tumour 2.8±0.2 3.1 ±0.5 2.4±0.4 2.7±0.2 2.6±0.3
Brain 0.22±0.09 0.13±0.04 0.135±0.037 0.118±0.041 0.116±0.026
Skin 1.87±0.38 2.08±0.51 1.76±0.33 1.22±0.31 1.11 ±0.26
TNP-4 (OH)
Blood 4.3±0.6 2.4±0.7 1.2±0.3 1.1±0.09 0.2±0.02
Liver 6.2± 1.2 9.6±0.8 9.1± 1.3 10.3±1.1 5.3±0.3
Spleen 38.6±2.3 66.5±4.1 67.0±2.2 66.0± 1.9 47.0± 1.3
Kidneys 1.8±0.3 1.3±0.5 1.2±0.4 1.0±0.2 0.6±0.2
Lungs 16.6±3.1 11.0±0.9 16.0± 1.7 24.7± 1.6 3.2±0.5
Tumour 0.7± 0.07 0.6±0.1 0.7±0.06 0.6±0.02 0.2±0.02
TNP-4 (OH)
Blood 13.7±2.2 6.3± 1.1 3.5±0.7 1.3±0.4 0.4±0.06
Liver 17.4± 3.1 21.2±2.9 25.2±3.6 17.8±3.2 19.6±4.3
Spleen 27.7±2.6 22.1± 3.3 29.9±4.1 25.6±2.2 22.4± 1.8
Kidneys 3.2±0.4 3.0± 1.1 1.9±0.7 1.4±0.6 0.9±0.3
Lungs 8.3±2.1 6.3±2.2 2.5±0.9 2.3± 1.2 1.1±0.3
The high spleen uptake of the hydroxynaphthyl porphyrin
in tumour bearing mice was an unexpected finding. As stated
above this tumour causes splenomegaly in the host animals.
If this porphyrin precipitates or forms aggregates after injec-
tion, the high spleen uptake could simply be a reflection of
increased macrophage activity in the enlarged and stimulated
organ.
Finally, it must be concluded that, since most of the
injected hydroxyporphyrins appear to localise in normal tis-
sues, care should be exercised if they are to be used in
phototherapy lest unacceptable normal tissue reactions are
produced.
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